| Typicality: | 0.534 |
| Saliency: | 0.545 |
| currently | 16 | temporal |
| for five years | 8 | temporal |
| by the team’s pharmaceutical partner | 6 | other |
| drug → be in → development | 121 |
| drug → be under → development | 49 |
| drug → be in → active development | 4 |
| drug → be into → development | 3 |
| drug → be under → active development | 3 |
| negative | neutral | positive |
| 0.149 | 0.641 | 0.210 |
| Raw frequency | 180 |
| Normalized frequency | 0.545 |
| Modifier score | 0.656 |
| Perplexity | 52.257 |